# NIH-sponsored clinical trials: 280 new since Nov 2024

Updated November 6, 2026.

280 clinical studies with a lead sponsor of class NIH were first posted on ClinicalTrials.gov from November 12, 2024 to November 6, 2026; 0 have an industry sponsor and 221 are recruiting or about to. The newest, NCT07920952, was posted on November 6, 2026: Effects of Ad Libitum Ultra-Processed Diet on Brain Dopamine in Humans (National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)).

## The full list

New NIH-funded clinical trials: 280 rows for $14, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 9 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/sponsor/nih

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 280
- Industry sponsored: 0
- Recruiting or not yet: 221
- Latest posted: November 6, 2026

## Newest trials

The newest 100 of 280, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 6, 2026 | NCT07920952 | Effects of Ad Libitum Ultra-Processed Diet on Brain Dopamine in Humans | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Not applicable | Not yet recruiting | Healthy Volunteers | 140 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920952) |
| November 4, 2026 | NCT07916259 | The Study of Brave-LC LDN Treatment Trial | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 | Not yet recruiting | Post-acute COVID-19 Syndrome | 1,300 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07916259) |
| November 4, 2026 | NCT07914855 | Testing the Anti-cancer Drug DSP-5336 (Enzomenib) in Prostate Cancer | National Cancer Institute (NCI) | Phase 2 | Not yet recruiting | Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | 24 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914855) |
| October 29, 2026 | NCT07902921 | STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic... | National Cancer Institute (NCI) | Phase 1/2 | Not yet recruiting | NSCLC, Non-Small Cell Lung Cancer, Lung Cancer, Prostate Cancer, Thymic Epithelial Tumors, TETs, Thymic Carcinomas... | 67 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07902921) |
| October 23, 2026 | NCT07891286 | Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young Adults | National Cancer Institute (NCI) | Phase 2 | Not yet recruiting | LGCMN, Large and Giant Congenital Melanocytic Nevi, NF1, Solid Tumor, Pediatric Tumors, Neurocutaneous Melanocytosis... | 15 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07891286) |
| October 20, 2026 | NCT07884240 | A Clinical Study to Assess the Efficacy of Weekly Doxycycline Prophylaxis to Reduce Bacterial Sexually Transmitted Infections (STI) in... | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 | Not yet recruiting | Sexually Transmitted Infection (STI), Gonorrhea, Syphilis, Chlamydia | 580 | Botswana, Eswatini, Malawi, Uganda | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07884240) |
| October 20, 2026 | NCT07882173 | Epcoritamab as Consolidative Therapy for Waldenstr(SqrRoot)(Delta)m Macroglobulinemia (WM) Treated With a Bruton Tyrosine Kinase Inhibitor... | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 | Not yet recruiting | Waldenstrom Macroglobulinemia | 24 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07882173) |
| October 20, 2026 | NCT07882160 | Metabolic Impact of VLCPUFA-Rich Fish Oil: A Clinical Study on Omega-3 Index Enhancement in Healthy Individuals | National Heart, Lung, and Blood Institute (NHLBI) | Not applicable | Recruiting | Fatty Acids, Omega-3, Fish Oils | 200 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07882160) |
| October 19, 2026 | NCT07881809 | A Clinical Study of Ixazomib to Reactivate HIV and Reduce HIV Reservoir Size | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | Not yet recruiting | HIV (Human Immunodeficiency Virus) | 45 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881809) |
| October 16, 2026 | NCT07877259 | Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use | National Institutes of Health Clinical Center (CC) | Observational | Not yet recruiting | Blood Donors, Apheresis | 5,000 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07877259) |
| October 16, 2026 | NCT07877246 | A Longitudinal Natural History Study of Immune Biomarkers in Neuropsychiatric Illness | National Institute of Mental Health (NIMH) | Observational | Recruiting | Neuropsychiatric Disorders, Neuroinflammatory Disorders, Post-Infectious Neuropsychiatric Disorders | 5,000 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07877246) |
| October 9, 2026 | NCT07867184 | Firefighter's Longitudinal Airway and Respiratory Exposome/Multiome Study (FLARES) | National Institute of Allergy and Infectious Diseases (NIAID) | Observational | Enrolling by invitation | Anosmia, Chronic Obstructive Pulmonary Disease, Hyposmia, Chronic Rhinosinusitis, Asthma | 350 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07867184) |
| October 7, 2026 | NCT07862517 | Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of... | National Cancer Institute (NCI) | Phase 2 | Not yet recruiting | Acute Myeloid Leukemia | 122 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07862517) |
| October 6, 2026 | NCT07859800 | Positron Emission Tomography and Organ-Specific Changes in Participants Co-Enrolled in NIH Studies of Plasmodium Vivax Controlled Human... | National Institute of Allergy and Infectious Diseases (NIAID) | Not applicable | Not yet recruiting | Healthy Volunteer, Malaria | 45 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07859800) |
| October 2, 2026 | NCT07853781 | First-in-Human Evaluation of \[11C\]JMJ-129-d2 for PDE4D Imaging in Healthy Volunteers | National Institute of Mental Health (NIMH) | Phase 1 | Recruiting | Healthy | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07853781) |
| September 21, 2026 | NCT07829497 | Pain Phenotyping of Rheumatic Diseases - An Observational Study | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Observational | Recruiting | Rheumatic Diseases, Lupus Erythematosus, Systemic, Lupus Vasculitis, Central Nervous System, Arthritis... | 225 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07829497) |
| September 14, 2026 | NCT07818824 | A Clinical Study of the HCMV-TB Vaccine Candidate VIR-1778 in Healthy Adults | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | Not yet recruiting | Tuberculosis | 116 | Peru | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07818824) |
| September 8, 2026 | NCT07806149 | NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices | National Heart, Lung, and Blood Institute (NHLBI) | Not applicable | Not yet recruiting | Hypertrophic Cardiomyopathy, Left Ventricular Outflow Obstruction, Systolic Anterior Motion | 200 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07806149) |
| September 3, 2026 | NCT07801456 | A Clinical Study to Evaluate the Safety and Immunogenicity of a Higher Dose of the Study Vaccine, VIR-1388, in HCMV-seropositive Adult... | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | Not yet recruiting | Cytomegalovirus (CMV), HIV (Human Immunodeficiency Virus) | 12 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07801456) |
| September 3, 2026 | NCT07801079 | Ecological Momentary Assessment of State-Dependent Decision-Making and Metacognition Across a Psychopathology Continuum | National Institute of Mental Health (NIMH) | Observational | Not yet recruiting | Depression, Anxiety, Addiction, Emotion, Craving, Stress | 420 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07801079) |
| September 2, 2026 | NCT07798908 | Noninvasive Neuromodulation Of The Subjective Value Network In Chronic Pain | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 1 | Not yet recruiting | Chronic Neurogenic Pain | 9 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07798908) |
| September 1, 2026 | NCT07796373 | Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase... | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 | Not yet recruiting | Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia | 32 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07796373) |
| September 1, 2026 | NCT07796360 | Dynamic Magnetic Resonance Imaging of Human Subarachnoid Space Using Intrathecal Gadolinium Contrast | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 1 | Not yet recruiting | Healthy Volunteers | 15 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07796360) |
| August 21, 2026 | NCT07778459 | Expanding HOPE Liver | National Institute of Allergy and Infectious Diseases (NIAID) | Observational | Recruiting | HIV Infection, Liver Transplant | 80 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07778459) |
| August 20, 2026 | NCT07775313 | Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1/2 | Enrolling by invitation | WHIM, Warts, Hypogammaglobulinemia, Immunodeficiency, Myelokathexis | 10 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07775313) |
| August 17, 2026 | NCT07768215 | Miniature In-line Respirator | National Institutes of Health Clinical Center (CC) | Not applicable | Not yet recruiting | Brain Death, Respiration, Artificial | 5 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07768215) |
| August 14, 2026 | NCT07764536 | Augmenting Parent Management Training for Child Temper Outbursts Using a Digital Tool | National Institute of Mental Health (NIMH) | Observational | Recruiting | Disruptive Behavior Disorders, Conduct Disorder, Oppositional Defiant Disorder, Attention-deficit/Hyperactivity Disorder | 200 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07764536) |
| August 11, 2026 | NCT07757802 | Phase 1 Study of CH505 HIV Vaccine Nanoparticles and mRNA Boosters in Healthy Adults | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | Recruiting | HIV | 54 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07757802) |
| August 11, 2026 | NCT07756853 | Visual Attention, Object Recognition, and Eye Movements in Healthy Volunteers | National Eye Institute (NEI) | Observational | Recruiting | Healthy Volunteer | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07756853) |
| August 11, 2026 | NCT07756840 | Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP) | National Cancer Institute (NCI) | Phase 2 | Not yet recruiting | Respiratory Recurrent Papillomatosis (RRP), Human Papillomavirus (HPV), Papillomavirus Infection, Laryngeal Diseases... | 50 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07756840) |
| August 7, 2026 | NCT07751731 | Survey to Determine Incarcerated Persons' Views on Surrogate Decision Making | National Institutes of Health Clinical Center (CC) | Observational | Recruiting | Healthy Volunteers | 75,000 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07751731) |
| July 30, 2026 | NCT07735741 | Immune Dysregulation During Sepsis: A Natural History Cohort | National Heart, Lung, and Blood Institute (NHLBI) | Observational | Not yet recruiting | Sepsis, Septic Shock, Sepsis-Associated Immune Dysregulation | 500 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07735741) |
| July 24, 2026 | NCT07724457 | Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma | National Cancer Institute (NCI) | Phase 2/3 | Not yet recruiting | Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Refractory Burkitt... | 271 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07724457) |
| July 23, 2026 | NCT07721467 | Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin | National Institute on Aging (NIA) | Phase 2 | Recruiting | Alzheimer's Disease | 200 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07721467) |
| July 21, 2026 | NCT07715903 | Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump... | National Cancer Institute (NCI) | Phase 1 | Not yet recruiting | Colorectal Neoplasms, Neoplasms, Intrahepatic Cholangiocarcinoma, Adrenocortical Carcinoma, Metastasis, Neoplasm | 20 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07715903) |
| July 21, 2026 | NCT07715890 | Plasma Lipids-Dependent Vitamin E Metabolism During Dynamic Hyperlipidemia | National Heart, Lung, and Blood Institute (NHLBI) | Not applicable | Not yet recruiting | Lipid Metabolism Disorders | 48 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07715890) |
| July 20, 2026 | NCT07712874 | Screening Protocol | National Center for Complementary and Integrative Health (NCCIH) | Observational | Not yet recruiting | Pain | 10,000 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07712874) |
| July 16, 2026 | NCT07706686 | Phase 1 Challenge Study Using rDEN2delta30-7169 to Evaluate Host-Pathogen Interactions in Primary, Homotypic, and Heterotypic Dengue Virus... | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | Recruiting | Healthy Volunteers, Dengue, Human Challenge Trial | 200 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07706686) |
| July 16, 2026 | NCT07706673 | ESCUDDO Long Term Follow Up | National Cancer Institute (NCI) | Phase 4 | Enrolling by invitation | Human Papillomavirus Infection, Human Papillomavirus-Related Malignant Neoplasm | 13,700 | Costa Rica | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07706673) |
| July 15, 2026 | NCT07704333 | Assessment of \[18F\]-Fluorocellobiose (\[18F\]FCB) Pharmacokinetics in Healthy Volunteers and Subjects With Invasive Mold Infections | National Institutes of Health Clinical Center (CC) | Phase 1 | Recruiting | Aspergillos, Mucormye, Dimorphic, Other Molds, Non-Aspergillos, Non-Mucormycosis | 98 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07704333) |
| July 14, 2026 | NCT07703514 | Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | Not yet recruiting | Influenza | 60 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07703514) |
| July 14, 2026 | NCT07703475 | A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | Not yet recruiting | COVID -19 | 80 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07703475) |
| July 14, 2026 | NCT07700511 | Healthy Volunteer Recruitment and Characterization for NINDS Studies | National Institute of Neurological Disorders and Stroke (NINDS) | Observational | Not yet recruiting | Healthy | 500 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07700511) |
| July 8, 2026 | NCT07689240 | Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma | National Cancer Institute (NCI) | Phase 3 | Not yet recruiting | Non-Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8 | 400 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07689240) |
| July 7, 2026 | NCT07686393 | PET Imaging of Noradrenergic Transmission in the Brain | National Institute of Mental Health (NIMH) | Phase 1 | Recruiting | Healthy | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07686393) |
| July 7, 2026 | NCT07686380 | IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy | National Cancer Institute (NCI) | Phase 2 | Recruiting | Recurrent Prostate Cancer, Prostate Cancer | 65 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07686380) |
| July 7, 2026 | NCT07686367 | Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers | National Cancer Institute (NCI) | Phase 2 | Not yet recruiting | Metastatic Myxoid Liposarcoma, Metastatic Synovial Sarcoma, Unresectable Myxoid Liposarcoma, Unresectable Synovial... | 42 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07686367) |
| July 6, 2026 | NCT07683104 | Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disorders | National Institute of Allergy and Infectious Diseases (NIAID) | Observational | Recruiting | Trisomy 8 Mosaicism, Trisomy 8 Associated Autoinflammatory Disease, Mucosal Ulcerations | 750 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07683104) |
| July 6, 2026 | NCT07683026 | Platform Trial in Stage 1 Diabetes: Comparing Golimumab vs Placebo | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 | Not yet recruiting | Type 1 Diabetes (T1D) | 255 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07683026) |
| June 29, 2026 | NCT07672483 | IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors | National Cancer Institute (NCI) | Phase 1 | Recruiting | Relapsed Solid Tumor Malignancies, Refractory Solid Tumor Malignancies | 95 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07672483) |
| June 25, 2026 | NCT07667400 | Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer | National Cancer Institute (NCI) | Phase 1/2 | Recruiting | Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Paranasal Sinus Neoplasms, Nasopharyngeal Carcinoma... | 120 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07667400) |
| June 16, 2026 | NCT07649317 | Ketoconazole Effects on the Daily Cortisol Rhythm in Mild Autonomous Cortisol Secretion | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 1 | Recruiting | Mild Autonomous Cortisol Secretion | 36 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07649317) |
| June 16, 2026 | NCT07649304 | AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") | National Cancer Institute (NCI) | Phase 1 | Recruiting | AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell... | 15 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07649304) |
| June 16, 2026 | NCT07649096 | A Safety Trial to Evaluate an Orally Ingested Yeast Modified to Express a Tetra-specific Anti-toxin for Clostridioides Difficile | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | Not yet recruiting | Clostridium Difficile Infection | 56 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07649096) |
| June 15, 2026 | NCT07647549 | Pulmonary Hypertension (PH) Biorepository for Translational Research | National Institutes of Health Clinical Center (CC) | Observational | Recruiting | Pulmonary Hypertension | 1,000 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07647549) |
| June 11, 2026 | NCT07640802 | Psychotherapy for Irritability in Youth: Comparing Active Treatment to Nonactive Psychoeducation Supportive Psychotherapy | National Institute of Mental Health (NIMH) | Observational | Recruiting | Irritability, Disruptive Mood Dysregulation Disorder, Oppositional Defiant Disorder, Attention Deficit Hyperactivity... | 410 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07640802) |
| June 10, 2026 | NCT07637669 | Olfactory Function and Model-Based Behavior in People Living With HIV and SUD | National Institute on Drug Abuse (NIDA) | Observational | Recruiting | HIV, Substance Use Disorder | 120 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07637669) |
| June 10, 2026 | NCT07637656 | Discovering Determinants of Food Intake by Application of Artificial Intelligence to Complex, High-Dimensional Data | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Observational | Not yet recruiting | Healthy Volunteer | 800 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07637656) |
| June 4, 2026 | NCT07625345 | Evaluation of \[11C\]ZTP-1 to Image PDE4B | National Institute of Mental Health (NIMH) | Phase 1 | Recruiting | Healthy | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07625345) |
| June 2, 2026 | NCT07619547 | Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Observational | Recruiting | Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis | 100 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07619547) |
| June 2, 2026 | NCT07619534 | Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior... | National Cancer Institute (NCI) | Observational | Recruiting | Breast Cancer, Breast Carcinoma, Cancer of the Breast, Malignant Neoplasm of Breast | 139 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07619534) |
| June 2, 2026 | NCT07619521 | Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal... | National Cancer Institute (NCI) | Phase 1/2 | Recruiting | Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer... | 31 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07619521) |
| May 29, 2026 | NCT07613112 | Longitudinal Natural History Protocol for PRKN- and PINK1-Linked PD | National Institute of Neurological Disorders and Stroke (NINDS) | Observational | Not yet recruiting | PARKINSON DIS | 70 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07613112) |
| May 29, 2026 | NCT07613099 | Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | Recruiting | Allogeneic Stem Cell Transplantation, Lung Allograft Transplantation, Interstitial Lung Disease, Acute Lung Injury... | 210 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07613099) |
| May 28, 2026 | NCT07611435 | Beginning to Assess an Appropriate CONtrol for Oral Food Challenges in Alpha-Gal Syndrome (CoFAR-13) - BeACON4AG | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | Recruiting | Alpha-Gal Syndrome, Allergy | 160 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07611435) |
| May 26, 2026 | NCT07605416 | Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial | National Cancer Institute (NCI) | Phase 2 | Recruiting | Plasma Cell Leukemia | 74 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07605416) |
| May 20, 2026 | NCT07599176 | Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1/2 | Recruiting | Sickle Cell Disease, Beta-thalassemia | 90 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07599176) |
| May 19, 2026 | NCT07595042 | A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB) | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | Not yet recruiting | Tuberculosis | 900 | Argentina, Australia, Botswana, Brazil, Haiti, India, Kenya, Malawi, Mexico... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07595042) |
| May 8, 2026 | NCT07574541 | Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With... | National Cancer Institute (NCI) | Phase 2 | Recruiting | Adenocarcinoma, Prostate Cancer, Neoplasms, Carcinoma, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type | 52 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07574541) |
| May 7, 2026 | NCT07572136 | Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing... | National Cancer Institute (NCI) | Phase 1 | Recruiting | B-All, Acute Lymphoblastic Leukemia | 57 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07572136) |
| May 7, 2026 | NCT07572123 | Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant... | National Cancer Institute (NCI) | Phase 2/3 | Not yet recruiting | Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | 374 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07572123) |
| May 6, 2026 | NCT07569029 | A Trial to Evaluate the Safety and Tolerability of DV700P-RNA and DV701B1.1-RNA Immunization in Combination With Antiretroviral Analytical... | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | Recruiting | HIV | 42 | Argentina, Peru, United States, Zimbabwe | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07569029) |
| May 5, 2026 | NCT07566494 | Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 | Recruiting | Sickle Cell Disease, Hemolytic Anemia | 25 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07566494) |
| May 5, 2026 | NCT07566481 | Stress, Coping, and Sleep Health Study | National Institute of Environmental Health Sciences (NIEHS) | Observational | Not yet recruiting | Sleep | 70 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07566481) |
| May 5, 2026 | NCT07566468 | Role of Theta Frequency Oscillations in Proactive and Reactive Control Processes in Youth With Attention Deficit Hyperactivity Disorder... | National Institute of Mental Health (NIMH) | Observational | Recruiting | ADHD, Obsessive Compulsive Disorder (OCD), Healthy Volunteer | 110 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07566468) |
| April 30, 2026 | NCT07559500 | Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD) | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Phase 1 | Recruiting | Alcohol Use Disorder (AUD) | 176 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07559500) |
| April 27, 2026 | NCT07551596 | Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal... | National Cancer Institute (NCI) | Phase 2 | Recruiting | Colorectal Adenocarcinoma, Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8 | 20 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07551596) |
| April 24, 2026 | NCT07549503 | Early Signals of the Transition From Immune Quiescence to Activation in the Liver Allograft Microenvironment and in the Circulation | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | Recruiting | Liver Transplant | 100 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07549503) |
| April 24, 2026 | NCT07549490 | Human Experimental Models of Pain (HEMP) | National Center for Complementary and Integrative Health (NCCIH) | Not applicable | Not yet recruiting | Acute Pain | 25 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07549490) |
| April 21, 2026 | NCT07541209 | Safety and Efficacy of PTH-IA | National Institute of Dental and Craniofacial Research (NIDCR) | Phase 1/2 | Recruiting | Jansen's Metaphyseal Chondrodysplasia | 12 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07541209) |
| April 17, 2026 | NCT07536308 | A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in... | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | Active not recruiting | COVID-19 | 83 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07536308) |
| April 13, 2026 | NCT07524530 | Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers | National Cancer Institute (NCI) | Phase 2 | Not yet recruiting | Core Binding Factor Alpha Subunits, Hematologic Neoplasms, Leukemia, Lymphoma | 102 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07524530) |
| April 8, 2026 | NCT07516379 | GRAfT 2.0. A Multimodal Prospective Approach to Define the Mechanisms and Clinical Features of Acute and Chronic Rejection in Lung... | National Heart, Lung, and Blood Institute (NHLBI) | Observational | Recruiting | Lung Transplant, End Stage Lung Disease, Rejection | 100 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07516379) |
| April 8, 2026 | NCT07516366 | Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell... | National Cancer Institute (NCI) | Phase 2 | Recruiting | Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IV... | 16 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07516366) |
| April 6, 2026 | NCT07511049 | Intravenous Brincidofovir as an Antiviral for Treatment of Progressive Multifocal Leukoencephalopathy: A Pilot Study | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 2 | Recruiting | Progressive Multifocal Leukoencephalopathy | 24 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07511049) |
| April 3, 2026 | NCT07509034 | Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or... | National Cancer Institute (NCI) | Phase 1 | Recruiting | Recurrent Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer, Small Cell Lung Cancer, Small Cell Lung... | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07509034) |
| April 2, 2026 | NCT07508800 | Effects of Brief Nature Exposure on Brain Functioning and Stress Reactivity | National Institutes of Health (NIH) | Observational | Completed | Stress (Psychology) | 4 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07508800) |
| April 1, 2026 | NCT07504601 | Investigating the Analgesic Potential of (2R,6R)-HNK in Acute Pain in Healthy Volunteers | National Center for Complementary and Integrative Health (NCCIH) | Phase 2 | Not yet recruiting | Healthy Volunteers | 92 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07504601) |
| April 1, 2026 | NCT07504588 | Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for... | National Cancer Institute (NCI) | Phase 2 | Recruiting | Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube... | 87 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07504588) |
| March 31, 2026 | NCT07502586 | Turner Syndrome: Genetic Considerations | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Observational | Recruiting | Genetic | 500 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07502586) |
| March 30, 2026 | NCT07499128 | Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event | National Cancer Institute (NCI) | Not applicable | Enrolling by invitation | Cytokine Release Syndrome, Neoplasms, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Multiple Myeloma... | 136 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07499128) |
| March 24, 2026 | NCT07489378 | NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors | National Cancer Institute (NCI) | Observational | Recruiting | Very Rare Tumors, Very Rare Cancers, Other Solid Tumors, Solid Tumor, Pediatric Rare Tumors | 4,000 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07489378) |
| March 20, 2026 | NCT07484282 | Quality of Care for Adolescent and Young Adult (AYA) Patients Living With Serious or Advanced Cancer | National Cancer Institute (NCI) | Observational | Withdrawn | Cancer, Patients Living With Stage IV or Recurrent Cancer | 0 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07484282) |
| March 12, 2026 | NCT07468552 | Trial of Tirzepatide for the Treatment of Cannabis Use Disorder | National Institute on Drug Abuse (NIDA) | Phase 2 | Not yet recruiting | Cannabis Use Disorder | 100 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07468552) |
| March 11, 2026 | NCT07463820 | A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial) | National Cancer Institute (NCI) | Phase 2 | Not yet recruiting | Myelodysplastic Syndrome | 270 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07463820) |
| March 11, 2026 | NCT07463807 | Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib... | National Cancer Institute (NCI) | Phase 1/2 | Recruiting | Recurrent Multiple Myeloma, Refractory Multiple Myeloma | 162 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07463807) |
| March 4, 2026 | NCT07447869 | LYmph Node eXamination in Cat Allergen Immunotherapy | National Institute of Allergy and Infectious Diseases (NIAID) | Early phase 1 | Recruiting | Allergy | 16 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07447869) |
| March 3, 2026 | NCT07444723 | Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2/3 | Recruiting | Primary Hyperparathyroidism, Parathyroid Cancer, Multiple Endocrine Neoplasias, Heritable Hyperparathyroidism... | 193 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07444723) |
| March 3, 2026 | NCT07444710 | Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously... | National Cancer Institute (NCI) | Phase 1 | Not yet recruiting | Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma, Ann Arbor Stage IV Mantle Cell... | 16 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07444710) |
| February 27, 2026 | NCT07437976 | A Natural History of Genetic and Environmental Predictors of Pubertal Timing Among Youth With Obesity | National Institute of Environmental Health Sciences (NIEHS) | Observational | Not yet recruiting | Obesity | 400 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07437976) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| National Cancer Institute (NCI) | 95 | November 4, 2026 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 80 | November 4, 2026 |
| National Heart, Lung, and Blood Institute (NHLBI) | 18 | October 20, 2026 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 14 | November 6, 2026 |
| National Institute of Mental Health (NIMH) | 13 | October 16, 2026 |
| National Institutes of Health Clinical Center (CC) | 11 | October 16, 2026 |
| National Institute of Neurological Disorders and Stroke (NINDS) | 11 | September 2, 2026 |
| National Institute on Drug Abuse (NIDA) | 8 | June 10, 2026 |
| National Institute of Environmental Health Sciences (NIEHS) | 4 | May 5, 2026 |
| National Institute on Alcohol Abuse and Alcoholism (NIAAA) | 4 | April 30, 2026 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 4 | March 31, 2026 |
| National Institute on Aging (NIA) | 3 | July 23, 2026 |
| National Center for Complementary and Integrative Health (NCCIH) | 3 | July 20, 2026 |
| National Human Genome Research Institute (NHGRI) | 3 | April 29, 2025 |
| National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 2 | September 21, 2026 |
| National Institute of Dental and Craniofacial Research (NIDCR) | 2 | April 21, 2026 |
| National Eye Institute (NEI) | 1 | August 11, 2026 |
| National Institutes of Health (NIH) | 1 | April 2, 2026 |
| Anil Chaturvedi | 1 | December 3, 2025 |
| National Institute on Deafness and Other Communication Disorders (NIDCD) | 1 | September 2, 2025 |

## Conditions

| Condition group | New trials | Latest |
| --- | --- | --- |
| [COVID-19](https://specstream.ai/data/clinical-trials/condition/covid-19) | 10 | July 14, 2026 |
| [Neoplasms](https://specstream.ai/data/clinical-trials/condition/neoplasms) | 9 | July 21, 2026 |
| [Prostatic Neoplasms](https://specstream.ai/data/clinical-trials/condition/prostatic-neoplasms) | 8 | November 4, 2026 |
| [Leukemia, Myeloid, Acute](https://specstream.ai/data/clinical-trials/condition/leukemia-myeloid-acute) | 8 | October 7, 2026 |
| [Colorectal Neoplasms](https://specstream.ai/data/clinical-trials/condition/colorectal-neoplasms) | 8 | July 21, 2026 |
| [Influenza, Human](https://specstream.ai/data/clinical-trials/condition/influenza-human) | 8 | July 14, 2026 |
| [Alcoholism](https://specstream.ai/data/clinical-trials/condition/alcoholism) | 8 | April 30, 2026 |
| [Lung Neoplasms](https://specstream.ai/data/clinical-trials/condition/lung-neoplasms) | 7 | October 29, 2026 |
| Myelodysplastic Syndromes | 7 | July 6, 2026 |
| [Carcinoma, Non-Small-Cell Lung](https://specstream.ai/data/clinical-trials/condition/carcinoma-non-small-cell-lung) | 6 | October 29, 2026 |
| Coronavirus Infections | 6 | July 14, 2026 |
| [Breast Neoplasms](https://specstream.ai/data/clinical-trials/condition/breast-neoplasms) | 6 | June 2, 2026 |
| [HIV Infections](https://specstream.ai/data/clinical-trials/condition/hiv-infections) | 5 | August 21, 2026 |
| Virus Diseases | 5 | July 16, 2026 |
| Carcinoma | 5 | June 25, 2026 |
| Hypersensitivity | 5 | May 28, 2026 |
| [Multiple Myeloma](https://specstream.ai/data/clinical-trials/condition/multiple-myeloma) | 5 | March 30, 2026 |
| Malaria | 4 | October 6, 2026 |
| Tuberculosis | 4 | September 14, 2026 |
| [Psychological Well-Being](https://specstream.ai/data/clinical-trials/condition/psychological-well-being) | 4 | September 3, 2026 |
| [Recurrence](https://specstream.ai/data/clinical-trials/condition/recurrence) | 4 | September 1, 2026 |
| Laryngeal Neoplasms | 4 | June 25, 2026 |
| [Inflammation](https://specstream.ai/data/clinical-trials/condition/inflammation) | 4 | June 2, 2026 |
| [Pancreatic Neoplasms](https://specstream.ai/data/clinical-trials/condition/pancreatic-neoplasms) | 4 | June 2, 2026 |
| [Precursor Cell Lymphoblastic Leukemia-Lymphoma](https://specstream.ai/data/clinical-trials/condition/precursor-cell-lymphoblastic-leukemia-lymphoma) | 4 | May 7, 2026 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Phase 1](https://specstream.ai/data/clinical-trials/phase/phase-1) | 82 | October 2, 2026 |
| [Phase 2](https://specstream.ai/data/clinical-trials/phase/phase-2) | 69 | November 4, 2026 |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 67 | October 16, 2026 |
| [Phase 1/2](https://specstream.ai/data/clinical-trials/phase/phase-1-2) | 23 | October 29, 2026 |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 18 | November 6, 2026 |
| [Phase 3](https://specstream.ai/data/clinical-trials/phase/phase-3) | 12 | November 4, 2026 |
| [Phase 2/3](https://specstream.ai/data/clinical-trials/phase/phase-2-3) | 3 | July 24, 2026 |
| [Phase 4](https://specstream.ai/data/clinical-trials/phase/phase-4) | 3 | July 16, 2026 |
| [Early phase 1](https://specstream.ai/data/clinical-trials/phase/early-phase-1) | 3 | March 4, 2026 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).